Discovery of YK-029A, a novel mutant EGFR inhibitor targeting both T790 M and exon 20 insertion mutations, as a treatment for NSCLC

卷:258

Article

关键词: CELL LUNG-CANCER;    FACTOR RECEPTOR MUTATIONS;    TYROSINE KINASE INHIBITORS;    PHASE-II;    RESISTANCE;    CHEMOTHERAPY;    GEFITINIB;    OSIMERTINIB;    AMIVANTAMAB;    ERLOTINIB;   

DOI  :  10.1016/j.ejmech.2023.115590

来源: SCIE

【 摘 要 】

Although traditional EGFR-TKIs have advanced the treatment landscape of NSCLC with sensitive driver mutations (del19 or L858R), some NSCLC patients with EGFR exon 20 insertion mutations have been left with few effective therapies. The development of novel TKIs is still in progress. Herein, we describe the structure-guided design of a novel selective and orally bioavailable inhibitor, YK-029A, which could overcome both the T790 M mutations and exon 20 insertion of EGFR. YK-029A inhibited EGFR signaling, suppressed sensitive mutations and ex20ins of EGFR-driven cell proliferation, and was largely effective with oral administration in vivo. Furthermore, YK-029A exhibited significant antitumor activity in EGFRex20ins-driven patients-derived xenograft (PDX) models, preventing tumor progression or causing tumor regression at well-tolerated dosages. Based on the outcomes of preclinical efficacy and safety studies, YK-029A will enter phase III clinical trials for the treatment of EGFRex20ins NSCLC.

【 授权许可】

Free